Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with …
ZB Harboe, SR Hamm, L Pérez-Alós… - BMJ Open …, 2022 - bmjopenrespres.bmj.com
Introduction Responses to COVID-19 vaccination in patients with chronic pulmonary
diseases are poorly characterised. We aimed to describe humoral responses following two
doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired
responses. Methods Prospective cohort study including adults with chronic pulmonary
diseases and healthcare personnel as controls (1: 1). Blood was sampled at inclusion, 3
weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as …
diseases are poorly characterised. We aimed to describe humoral responses following two
doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired
responses. Methods Prospective cohort study including adults with chronic pulmonary
diseases and healthcare personnel as controls (1: 1). Blood was sampled at inclusion, 3
weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as …
[PDF][PDF] Antibody Responses and Risk Factors Associated With Impaired Immunological Outcomes Following Two Doses of BNT162b2 COVID-19 Vaccination in …
Z Barrella Harboe, SR Hamm, L Pérez-Alós… - papers.ssrn.com
Background: Responses to COVID-19 vaccination in patients with chronic pulmonary
diseases are poorly characterized. We aimed to describe humoral responses following two
doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired
responses. Methods: Prospective cohort study including adults with chronic pulmonary
diseases and health care personnel as controls (1: 1). Blood was sampled at inclusion, 3
weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as …
diseases are poorly characterized. We aimed to describe humoral responses following two
doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired
responses. Methods: Prospective cohort study including adults with chronic pulmonary
diseases and health care personnel as controls (1: 1). Blood was sampled at inclusion, 3
weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as …
以上显示的是最相近的搜索结果。 查看全部搜索结果